Top 10 Life Science VC (Venture Capital) Funds in Norway in January 2025
A list of 10 VC (Venture Capital) funds that invest in Life science startups based in Norway. We rank investors based on the number of investments they made in Life science companies from Norway. We update this investor list every month.Top 10 Life Science VC (Venture Capital) Funds in Norway in January 2025
Investor | Life Science Norway investments |
---|---|
Investinor | 2 |
Nordic Impact | 1 |
World Wildlife Fund | 1 |
Dynamk Capital | 1 |
Canica | 1 |
Bakken & Baeck | 1 |
Project Sandwater | 1 |
Hadean Ventures | 1 |
The Index Project | 1 |
Birk Venture | 1 |
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more
Investment focus
- Software, Biotechnology, Manufacturing
- Funding Round, Seed, Series A
- Norway, United States, Switzerland
Portfolio highlights
- Eyr — Eyr offers digital tools for medical consulting and doctor's prescription regarding various health issues.
- Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
- Ignite — A powerful & easy spend management tool to accelerate your procurement success by bringing clarity, clean data & sophisticated analytics to your fingertips
Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.
Show more
Investment focus
- Chemical, Life Science, Visual Search
- Seed
- Norway
Portfolio highlights
- Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.
World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.
Show more
Investment focus
- Seafood, Food Processing, Farming
- Seed, Series A, Funding Round
- Norway, Faroe Islands, United Kingdom
Portfolio highlights
- OCEANIUM — OCEANIUM is a world-leading developer of innovative, functional seaweed ingredients to catalyse the seaweed industry for People Health and Ocean Health.
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
- Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.
Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Seed, Series B
- United States, Canada, Norway
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
- Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more
Investment focus
- Beauty, Medical, Biotechnology
- Private Equity, Series A, Series D
- Norway, Denmark, Switzerland
Portfolio highlights
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
- Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Since 2011, we have built products with some of the most ambitious companies out there. From defining future homes with IKEA to building decentralised platforms with Coinbase.
Show more
Investment focus
- Chemical, Software, Life Science
- Seed, Angel
- Norway
Portfolio highlights
- Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
- Iris.ai — AI for scientific text understanding - Smart search, reading list analysis, auto-generated summaries, data extraction, chatbot with references.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more
Investment focus
- Medical, Consulting, Life Science
- Series A
- Norway, The Netherlands
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.
The funds are backed by leading private and institutional investors.
Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Sweden, Norway, Austria
Portfolio highlights
- SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
- Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?
Show more
Investment focus
- Artificial Intelligence, Chemical, SaaS
- Seed, Series A, Series B
- United States, Denmark, Chile
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Series A, Funding Round
- Norway, United Kingdom
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.
Investors by industry
Consumer
Hardware
Climate
Proptech
Gaming
Google
Marketplace
Biotech
Impact
Community
Energy
FinTech
Artificial intelligence
Health Care
EdTech
Sustainability
Venture Capital
Real Estate
Retail
Clean Energy
Food and Beverage
B2B
Video Games
Web3
Photography
Education
Big Data
Finance
Financial Services
Payments
Beauty
Publishing
Infrastructure
Organic Food
Social Network
Social Media
Digital Media
Art
Medical
Android
Franchise
Mobile
Local
Music
Legal
Enterprise Software
eSports
Construction
Sports
Internet
Wellness
Email
Manufacturing
Recruiting
Mobile Advertising
Travel
Hospitality
Cannabis
Fitness
Biotechnology
Platforms
Wine And Spirits
Automotive
Social
Medical Device
Crowdfunding
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Film
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Germany
United Kingdom
Canada
United States
New Zealand
South Korea
Ireland
India
Australia
Africa
Sri Lanka
Europe
Middle East
China
Qatar
Vietnam
Armenia
Oceania
Brazil
Indonesia
Asia
South Africa
Spain
Saudi Arabia
Japan
Singapore
LATAM
Estonia
Bermuda
Gibraltar
Belarus
Croatia
Ethiopia
Belize
Egypt
Georgia
France
Denmark
Costa Rica
Greece
Czech Republic
Hungary
Ecuador
Faroe Islands
Chile
Ghana
Finland
Bahrain
Algeria
Hong Kong
Belgium
Bulgaria
Liechtenstein
Mauritius
Lithuania
Italy
Barbados
Philippines
Mali
Liberia
Jersey
Malaysia
Senegal
Israel
Malta
Lebanon
Norway
Myanmar
Uruguay
Morocco
Peru
Puerto Rico
Nicaragua
Mexico
Sweden
Panama
Kuwait
El Salvador
Dominican Republic
Sierra Leone
Uganda
Slovenia
Taiwan
Bahamas
Iceland
Namibia
Nigeria
Azerbaijan
Togo
Iraq
Seychelles
United Arab Emirates
Jamaica
Honduras
Zambia
Isle of Man
Bolivia
Venezuela
Luxembourg
Tajikistan
Zimbabwe
Russian Federation
Albania
Pakistan
Turkey
Tunisia
Uzbekistan
Thailand
Rwanda
San Marino
Serbia
Jordan
Bangladesh
Argentina
Romania
Grenada
Tanzania
Ukraine
Portugal
Poland
Kazakhstan
Kenya
Cayman Islands
Cambodia
Cameroon
Cyprus
Latvia
Oman
Austria
Switzerland
Colombia
Guatemala
Marshall Islands
VC (Venture Capital) Funds in Norway by industry
Clean Energy
Oil and Gas
Transportation
Financial Services
Big Data
Payments
Food and Beverage
Medical
Medical Device
Internet
Social Media
Manufacturing
Music
Mobile
Construction
Software
Enterprise Software
Sports
CleanTech
EdTech
FinTech
Enterprise
Consumer
Climate
Sustainability
Energy
Proptech
Impact
SaaS
Marketplace
Artificial intelligence
Community
Hardware
Gaming
Social
Web3
B2B
Retail
Life Science
Fashion
Education
Biotechnology
Real Estate
Health Care
Biotech
Publishing
Renewable Energy
Cryptocurrency
Blockchain
Video Games
Media (entertainment)
Agriculture (agtech)